Gapping down
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- SCHL -12.5% (also increases repurchase program by $66 mln), NX -8.5%, RICK -3.7%, LEN -2.5%, DRI -0.8%
Other news:
- AADI -50.3% (reports interim results from PRECISION1 Trial)
- EOSE -20.2% (prices $50 mln offering consisting of common stock and warrants)
- HRTG -7.9% (prices 3703703 share offering at $6.75 per share)
- CGEM -5.4% (first patient dosed in Phase 1 trial of CLN-617)
- COOK -4.8% (voluntary recall of its Flatrock Griddle; reiterates FY23 guidance)
- SNDX -4.4% (prices offering of 10810810 shares of common stock at $18.50 per share)
- BLBD -4.3% (2.5 mln share offering by selling shareholders)
- SGRY -4.1% (8 mln share offering by selling shareholders)
- NYMT -3% (decreases dividend)
- KRTX -1.8% (Announces The Lancet Publication of Data from Phase 3 EMERGENT-2 Trial Evaluating KarXT in Schizophrenia)
- IOAC -1.8% (Nasdaq hearing has been rescheduled to February 20 2024; expects the Business Combination to be completed prior to the hearing date)
- NAUT -1.3% (NAUT files patent suit against SLGC)
- SHIP -1.1% (share capital accretion plan and open market stock purchases by CEO)
Analyst comments:
- TSCO -2.1% (downgraded to Underperform from Neutral at BofA Securities)
- ROKU -2.1% (downgraded to Sell from Market Perform at MoffettNathanson)
- GFS -1.6% (downgraded to Neutral from Buy at BofA Securities)
- KMB -1% (downgraded to Underperform from Neutral at BofA Securities)
- CMI -0.9% (downgraded to Neutral from Buy at BofA Securities)
- DOCU -0.5% (downgraded to Outperform from Buy at Daiwa Securities)